We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+64.04%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.61B
AUM Growth
+$301M
(+13%)
Cap. Flow
-$35.3M
Cap. Flow
% of AUM
-1.36%
Top 10 Holdings %
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$114M |
| 2 |
Krystal Biotech
KRYS
|
+$66.7M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$24.2M |
| 4 |
Cogent Biosciences
COGT
|
+$23.6M |
| 5 |
Zimmer Biomet
ZBH
|
+$20.6M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$102M |
| 2 |
argenx
ARGX
|
+$48.6M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$41.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$31.2M |
Sector Composition
| 1 | Healthcare | 97.02% |
| 2 | Industrials | 2.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $335M | 12.84% |
17,730,417
+9,684,200
| +120% | +$114M |
|
|
2
Krystal Biotech
KRYS
$10.2B
| $301M | 11.57% |
2,566,661
+653,381
| +34% | +$66.7M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $246M | 9.43% |
19,566,961
+1,220,100
| +7% | +$14.5M |
|
4
Replimune Group
REPL
$824M
| $103M | 3.94% |
4,420,533
+608,545
| +16% | +$11.9M |
|
|
AKRO
5
DELISTED
Akero Therapeutics
AKRO
| $84.6M | 3.25% |
1,811,672
-232,717
| -11% | -$10.7M |
|
|
AUGX
6
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $75.2M | 2.89% |
15,630,327
+1,250,000
| +9% | +$4.32M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $68.7M | 2.64% |
4,878,566
-703,539
| -13% | -$10.1M |
|
8
Fate Therapeutics
FATE
$336M
| $62.5M | 2.4% |
13,124,427
+167,205
| +1% | +$923K |
|
9
Celldex Therapeutics
CLDX
$3.01B
| $57.5M | 2.21% |
1,696,004
-183,735
| -10% | -$6.19M |
|
10
LivaNova
LIVN
$4.4B
| $56.6M | 2.17% |
1,100,492
-85,926
| -7% | -$4.03M |
|
|
CTLT
11
DELISTED
CATALENT, INC.
CTLT
| $50.4M | 1.93% |
1,162,166
+551,862
| +90% | +$24.2M |
|
12
Zymeworks
ZYME
$1.81B
| $48.9M | 1.88% |
5,661,230
-406,688
| -7% | -$3.64M |
|
13
Pliant Therapeutics
PLRX
$68.7M
| $48.5M | 1.86% |
2,678,099
-247,549
| -8% | -$5.86M |
|
14
Penumbra
PEN
$12.5B
| $47.8M | 1.84% |
138,970
-49,022
| -26% | -$15.1M |
|
15
Beam Therapeutics
BEAM
$3.13B
| $47.4M | 1.82% |
1,485,199
-126,895
| -8% | -$4.12M |
|
16
Xenon Pharmaceuticals
XENE
$6.52B
| $43.1M | 1.66% |
1,120,476
-205,356
| -15% | -$8.16M |
|
17
Kymera Therapeutics
KYMR
$9.3B
| $43M | 1.65% |
1,868,507
-542,262
| -22% | -$15.5M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.4B
| $42.4M | 1.63% |
489,208
+154,038
| +46% | +$14.5M |
|
19
Jazz Pharmaceuticals
JAZZ
$15.1B
| $42.4M | 1.63% |
341,882
+6,723
| +2% | +$905K |
|
20
Stoke Therapeutics
STOK
$1.84B
| $42M | 1.61% |
3,955,188
-190,208
| -5% | -$2.02M |
|
21
Regenxbio
RGNX
$622M
| $40.5M | 1.55% |
2,026,576
+385,851
| +24% | +$7.43M |
|
22
DexCom
DXCM
$28.7B
| $37.2M | 1.43% |
289,161
-46,887
| -14% | -$5.67M |
|
23
Immunovant
IMVT
$8.07B
| $36.4M | 1.4% |
1,921,152
+604,121
| +46% | +$11.3M |
|
24
Elevance Health
ELV
$84.6B
| $34.8M | 1.34% |
78,313
+11,915
| +18% | +$5.5M |
|
25
Scholar Rock
SRRK
$6.46B
| $33.2M | 1.27% |
4,403,840
+1,279,614
| +41% | +$9.66M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO